TQB 2928
Alternative Names: TQB-2928Latest Information Update: 16 Aug 2024
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action CD47 antigen inhibitors; SIRPA protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Haematological malignancies; Lymphoma; Myelodysplastic syndromes; Osteosarcoma; Solid tumours
Most Recent Events
- 31 Jul 2024 Chia Tai Tianqing Pharmaceutical terminates phase-I clinical trials in Solid tumours and Lymphoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in China (Parenteral), based on the current status of the same target research and the company's overall layout in the field of tumors(NCT06297642)
- 24 May 2024 Phase-I clinical trials in Lymphoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in China (Parenteral) (NCT06297642)
- 24 May 2024 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in China (Parenteral) (NCT06297642)